News

Although neutropenic fever was common among patients, there was no significant difference between disease-modifying therapies, including those with long-lasting effects.

The director of the MedStar Georgetown Headache Center shared her clinical understanding of new therapies for migraine and how the paradigm shift in care has altered the experience for both patients and physicians.

The founder and chief medical officer of Omniscient Neurotechnology provided commentary on expanding the brain map, the use of advanced technology, and the need to familiarize clinicians with connectomics.

The executive director of the Bensalem Rescue Squad spoke specifically to how the MSU has shifted the paradigm of care that EMS can provide to individuals in the community. [WATCH TIME: 4 minutes]

The new ASA/AHA guidance, updating the prior 2015 publication, provides several significant recommendations and changes, including those for the use of antiseizure medications in patients with ICH.

In 2 pivotal trials, the agent showed statistically significant superiority over placebo at 2 hours on coprimary end points of pain freedom and freedom from the most bothersome symptom.

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]

In total, 14% of those on antiseizure medication who did not receive periconceptional folic acid experienced preterm birth compared with 5% of those with supplementation.

A year after the 2021 ASA/AHA stroke prevention guidelines were released, experts in the field shared some of the most notable changes to care, and the areas that still need to be addressed going forward.

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]

Resective epilepsy surgery was generally associated with good outcomes regarding employment status, seizure reduction, and antiseizure medication reduction.

In total, 65% of those who self-discontinued treatment experienced further seizure recurrence, which led to a majority (84%) of patients restarting treatment.

The founder and chief medical officer of Omniscient Neurotechnology provided insight on the successes using connectomics, including the FDA approval of Quicktome, a digital brain mapping platform. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Despite good tolerability with few drug-related treatment emergent AEs and increased muscle volume, the failure to provide clinically relevant improvements in muscle function led to the discontinuation of ACE-083 for CMT in 2020.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuropathic disorders.

If approved, ABBV-951 would become the first subcutaneous delivery of levodopa and carbidopa, the gold standard for symptom management in Parkinson disease.

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 20, 2022.

The founder and chief medical officer of Omniscient Neurotechnology discussed the idea behind connectomics and how AI revolutionizes large-scale brain data. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Matthew B. Harms, MD. [LISTEN TIME: 28 minutes]

The chief of emergency medical services at Jefferson Health shared his perspective on the first 2 years of the Jefferson MSU’s use and what takeaways he has gleaned from the experience. [WATCH TIME: 3 minutes]

The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]

At the end of the 12-month treatment period, interseizure cluster intervals increased from 14.8 days in the first period to 35.8 days in the final 90-day stretch.

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]

A PK/PD model indicated that a higher concentration of nusinersen may predict an additional 5-point increase in CHOP-INTEND score beyond that observed with the approved 12-mg dose.

In preataxia individuals, serum neurofilament levels increased with proximity to predicted ataxia onset, with significant elevations already present 5 years before onset.

In this episode of Connecting ALS, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

The blood test from Diadem SpA, which quantifies the AZ 284 peptide as readout of U-p53AZ, showed a significantly higher AUC in both time-independent and time-dependent prognostic analyses than gold standard testing.